Talk Presenting Companies (Theatre B) track
Cell and Gene Therapies: Surginex
Mon, Nov 9, 2026 · 1:30–1:45 PM CET Koelnmesse
About this session
Surginex is a Seoul-based biotech developing next-generation ionizable lipids and organ-targeted lipid nanoparticles (LNPs) for RNA and gene therapy. Founded in 2020 and a JLABS Korea portfolio company, Surginex built its pipeline on two proprietary ionizable lipids, RX-167 for therapeutics and RX-171 for vaccines, each protected by composition-of-matter and formulation patents filed in Korea, the United States, Europe, Japan and China, with freedom-to-operate secured. RX-167 is engineered for repeat intravenous dosing, a limitation of most approved LNPs.
Speaker
-
Vice-President · Surginex
Speaker